Business · 28/03/2016Updated: 10/17/2026 · 1 min read
FDA Amends Regulations for Biological Products and Bioequivalence
Summary
The US Food and Drug Administration (FDA) is updating its regulations to correct a typographical error in the address for submitting investigational new drug applications (INDs) for biological products, as well as revising bioequivalence regulations to ensure accuracy and clarity.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →